Shi Fang

Shi Fang

Auto-generated profile, based on publicly available information

Shi Fang

Heart and Vascular Institute, Mass General Brigham; Boston, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2021 in Circulation Research
Verified
Journal Article
Closed access
PDF file
SFShi Fang
Shi Fang
MLM. Christine Livergood
M. Christine Livergood
PNPablo Nakagawa
Pablo Nakagawa
JWJing Wu
Jing Wu
CSCurt D. Sigmund
Curt D. Sigmund
Nuclear receptors represent a large family of ligand-activated transcription factors which sense the physiological environment and make long-term adaptations by mediating changes in gene expression. In this review, we will first discuss the fundamental mechanisms by which nuclear receptors mediate their transcriptional responses. We will focus on the PPAR (peroxisome proliferator-activated receptor) family of adopted orphan receptors paying special attention to PPARγ, the isoform with the most compelling evidence as an important regulator of arterial blood pressure. We will review genetic data showing that rare mutations in PPARγ cause severe hypertension and clinical trial data which show that PPARγ activators have beneficial effects on blood pressure. We will detail the tissue- and cell-specific molecular mechanisms by which PPARs in the brain, kidney, vasculature, and immune system modulate blood pressure and related phenotypes, such as endothelial function. Finally, we will discuss the role of placental PPARs in preeclampsia, a life threatening form of hypertension during pregnancy. We will close with a viewpoint on future research directions and implications for developing novel therapies.

9 May 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
SFShi Fang
Shi Fang
JWJing Wu
Jing Wu
JRJohn J. Reho
John J. Reho
KLKo-Ting Lu
Ko-Ting Lu
DBDaniel T. Brozoski
Daniel T. Brozoski
CSCurt D. Sigmund
Curt D. Sigmund
Arterial stiffness predicts cardiovascular disease and all-cause mortality, but its treatment remains challenging. Mice treated with angiotensin II (Ang II) develop hypertension, arterial stiffness, vascular dysfunction, and a downregulation of Rho-related BTB domain–containing protein 1 (RhoBTB1) in the vasculature. RhoBTB1 is associated with blood pressure regulation, but its function is poorly understood. We tested the hypothesis that restoring RhoBTB1 can attenuate arterial stiffness, hypertension, and vascular dysfunction in Ang II–treated mice. Genetic complementation of RhoBTB1 in the vasculature was achieved using mice expressing a tamoxifen-inducible, smooth muscle–specific RhoBTB1 transgene. RhoBTB1 restoration efficiently and rapidly alleviated arterial stiffness but not hypertension or vascular dysfunction. Mechanistic studies revealed that RhoBTB1 had no substantial effect on several classical arterial stiffness contributors, such as collagen deposition, elastin content, and vascular smooth muscle remodeling. Instead, Ang II increased actin polymerization in the aorta, which was reversed by RhoBTB1. Changes in the levels of 2 regulators of actin polymerization, cofilin and vasodilator-stimulated phosphoprotein, in response to RhoBTB1 were consistent with an actin depolymerization mechanism. Our study reveals an important function of RhoBTB1, demonstrates its vital role in antagonizing established arterial stiffness, and further supports a functional and mechanistic separation among hypertension, vascular dysfunction, and arterial stiffness.

1 March 2021 in Hypertension
Verified
Journal Article
Closed access
PDF file
JWJing Wu
Jing Wu
SFShi Fang
Shi Fang
KLKo-Ting Lu
Ko-Ting Lu
KWKelsey Wackman
Kelsey Wackman
MSMichal L. Schwartzman
Michal L. Schwartzman
CSCurt D. Sigmund
Curt D. Sigmund
We previously showed that impaired vasodilation in systemic and renal vessels contributes to salt-sensitive hypertension in a mouse model of impaired PPARγ (peroxisome proliferator-activated receptor gamma) function. We determined the mechanisms mediating impaired salt-induced vasodilation and whether improved vasodilation attenuates augmented hypertension in response to salt. Mice selectively expressing a PPARγ dominant negative mutation in vascular smooth muscle (S-P467L) exhibited salt-sensitive hypertension and severely impaired vasodilation in systemic and renal vessels. High-salt diet–fed S-P467L and control mice displayed comparable levels of renal oxidative stress markers. Preincubation with Tempol, a superoxide dismutase mimetic, or calphostin C, a PKC (protein kinase C) inhibitor, failed to improve salt-induced impairment of vasodilation in S-P467L mice, arguing against a role of oxidative stress or PKC activity. Inhibition of Rho kinase partially rescued impaired vasodilation in high-salt diet–fed S-P467L mice suggesting a contribution of the Ras homolog family member A (RhoA)/Rho kinase pathway. High-salt diet selectively increased synthesis of PGE2 (prostaglandin E2) in S-P467L aorta. Expression of EP3 (E-prostanoid 3) receptor mRNA was increased in aorta from chow-fed and high salt–fed S-P467L mice. Pharmacological inhibition of COX (cyclooxygenase) 2 or blockade of EP3 completely normalized the impaired vasodilation, and EP3 antagonism induced larger decreases in systolic blood pressure in high-salt diet–fed S-P467L mice. In conclusion, interference with PPARγ in vascular smooth muscle causes activation of the PGE2/EP3 signaling pathway in systemic and renal vasculature resulting in salt-induced impairment of vasodilation and salt-sensitive hypertension. PGE2/EP3 axis maybe a druggable target to prevent salt-sensitive hypertension in chronic conditions associated with decreased PPARγ activity.

18 February 2016 in Food & Function
Verified
Journal Article
Closed access
PDF file
SSSheng Song
Sheng Song
LYLiu Yang
Liu Yang
MYMing Ye
Ming Ye
XCXue Chen
Xue Chen
FSFang Shi
Fang Shi
FSFarnaz Shaikh
Farnaz Shaikh
The present study aims to investigate the protective effects of an orally administered Lachnum YM226 melanin–iron complex (LM–Fe) against iron deficiency anemia (IDA) in mice. The IDA mouse model was established by feeding mice with iron-deficient food. Different doses of LM–Fe were given to the anaemic mice via intragastric administration, with FeCl3 and FeSO4 used as positive controls. After the iron supplement administration, it was observed that LM–Fe could significantly improve the decreased haemoglobin (Hb) level, and normalize the serum iron (SI) level, total iron-binding capacity (TIBC) and serum ferritin (SF) of the anaemic mice in a dose-dependent manner. In addition, treatment with LM–Fe significantly increased the antioxidant enzyme activities of superoxidase dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) in plasma to normal or better. Furthermore, the levels of tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6) were obviously decreased in the LM–Fe supplemented groups compared with the model group, while the level of interleukin-2 (IL-2) was significantly increased. In conclusion, LM–Fe was efficient at ameliorating the anemia symptoms, improving the activities of antioxidant enzymes and adjusting the immune dysfunction of anaemic mice. Thus, these results demonstrated that LM–Fe might be exploited as an efficient and multifunctional iron supplement.

14 May 2021 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
SFShi Fang
Shi Fang
JWJing Wu
Jing Wu
SSSebastiao Silva
Sebastiao Silva
JRJohn Reho
John Reho
KLKo‐Ting Lu
Ko‐Ting Lu
CSCurt Sigmund
Curt Sigmund
Rho‐related BTB domain‐containing protein (RhoBTB1) is a novel transcriptional target of peroxisome proliferator activated receptor Gamma (PPARg). The physiological and molecular function of RhoBTB1 is poorly understood. Human individuals carrying PPARg dominant negative mutation P467L develop early onset hypertension. Mice expressing smooth muscle‐specific P467L also develop hypertension, vascular dysfunction, and arterial stiffness. Interestingly, P467L‐mediated hypertension and its sequelae can be reversed by restoration of RhoBTB1 in smooth muscle, suggesting that RhoBTB1 mediates the anti‐hypertension effect of PPARg in vascular smooth muscle cells. We recently found that RhoBTB1 preserves the nitric oxide‐cGMP pathway by serving as a substrate adaptor for Cullin‐3 and promoting phosphodiesterase 5 ubiquitination. Our current study explores the role of RhoBTB1 in angiotensin II (Ang‐II) induced hypertension, a model that represents a broader hypertension population. We hypothesize that RhoBTB1 transgene expression in vascular smooth muscle will attenuate Ang‐II‐mediated hypertension and its sequelae. Mice expressing smooth muscle‐specific, Tamoxifen inducible RhoBTB1 transgene (S‐RhoBTB1) were used as experimental animals, whereas mice expressing smooth muscle‐specific, Tamoxifen inducible Cre‐recombinase (ISM‐Cre) were used as control. Mice received 6‐weeks of Ang‐II infusion via osmotic mini pump at 490ng/kg/min. Transgene was induced by five daily Tamoxifen injections two weeks after Ang‐II pumps implantation, allowing hypertension to be established before transgene activation. Blood pressure was monitored by radiotelemetry. Systolic, diastolic, and mean arterial blood pressure was significantly increased in response to Ang‐II. RhoBTB1 transgene expression was not sufficient to reverse the high blood pressure. We also tested vascular reactivity in conduit and resistant arteries using wire myography. Ang‐II infusion significantly impaired the vasodilation response to acetylcholine in carotid and mesenteric arteries, suggesting a defect in endothelium‐mediated vasodilation. Like blood pressure, RhoBTB1 transgene expression was not sufficient to reverse the vasodilation impairment. Finally, we measured arterial stiffness using pulse‐wave velocity (PWV). Both ISM‐Cre and S‐RhoBTB1 mice showed increased arterial stiffness two weeks after Ang‐II infusion, indicated by a higher PWV. PWV in S‐RhoBTB1 mice started to decline one‐week post Tamoxifen and became significantly lowered (nearly reversed) two weeks after Tamoxifen. In comparison, PWV in ISM‐Cre mice remained high till the end of the 6‐weeks protocol. To explore the underlying mechanism, we evaluated the aortic compliance using pressure myograph in the absence of vascular tone and reactivity. Both pressure‐diameter and stress‐strain relationship indicate that RhoBTB1 transgene expression in smooth muscle improved the compliance of aorta in the presence of Ang‐II, suggesting RhoBTB1 might attenuate arterial stiffness by acting on the extracellular matrix. Our study revealed a novel protective effect of RhoBTB1: attenuating established Ang‐II‐induced arterial stiffness.

30 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
SFShi Fang
Shi Fang
GSGavin R. Schnitzler
Gavin R. Schnitzler
AVAmélie Vromman
Amélie Vromman
JJJiahao Jiang
Jiahao Jiang
MMMohita Maurya
Mohita Maurya
RGRajat M. Gupta
Rajat M. Gupta
Genetic variants in the Cerebral Cavernous Malformation 2 ( CCM2 ) locus are associated with coronary artery disease (CAD), but the role of CCM2 in atherosclerosis is unknown. We previously identified CCM2 through endothelial cell (EC) Perturb-seq as a regulator of transcriptional programs enriched for CAD risk genes, and predicted that reduced CCM2 function would be athero-protective. Here, we integrated human genetics, functional studies in human aortic ECs, and single cell profiling with mouse models of atherosclerosis to define the effects of reduced CCM2 signaling across disease stages. Ccm2 +/- mice developed less atherosclerosis after 12 weeks of high-fat, high-cholesterol diet. At baseline, aortic ECs from Ccm2 +/- mice exhibited reduced inflammatory transcriptional programs, and CCM2 knockout in human aortic ECs increased KLF2 expression and reduced monocyte adhesion and procoagulant activity. However, this protective phenotype was not sustained during disease progression. After 12 weeks of high-fat, high-cholesterol diet, Ccm2 +/- mice exhibited increased circulating TNFα and increased inflammatory programs in aortic ECs and T cells. Consistent with this transition, Ccm2 +/- showed increased atherosclerotic burden after 20 weeks of atherogenic diet. Human genetic analyses showed a similar context-dependent association. The lead variant in the CCM2 locus (rs2107732, a missense V53I coding variant in CCM2 ) was associated with lower CAD risk in the general population but higher CAD risk in clinical trial cohorts enriched for cardiometabolic disease. These results demonstrate how the phenotypic consequences of a CAD-associated gene can depend on disease context and stage. One Sentence Summary: CCM2 heterozygosity reduces endothelial inflammation and early atherosclerosis but worsens late-stage disease, consistent with human genetics.